| ²é¿´: 150 | »Ø¸´: 1 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
zhoudanleiÒø³æ (СÓÐÃûÆø)
|
[½»Á÷]
20½ð±ÒÇóÖúÒ»¶Îµ°°×PEG ÐÞÊεķÒë
|
||
|
Ñо¿²ÉÓûùÒò¹¤³Ì·½·¨ÔÚµ°°×CÄ©¶ËÒýÈë×ÔÓÉÛÏ»ùÒÔ¼°ÀûÓÃС·Ö×ÓÌØÒìÐÔÐÞÊÎÔÚµ°°×CÄ©¶ËÒýÈëÑǰ·»ùÍŵķ½·¨£¬ÊµÐÐÄ¿±êµ°°×µÄPEG¶¨µãÐÞÊΣ¬»ñµÃÎȶ¨µÄÐÞÊβúÎΪÒÔºóÆäËüµ°°×ÖÊÒ©ÎïµÄ¶¨µãÐÞÊε춨»ù´¡¡£ ±¾ÏîÄ¿µÄÑо¿ÒâÒåÔÚÓÚ̽ÌÖÁ½ÖÖÒ©Óõ°°×ÖÊCÄ©¶ËµÄPEG¶¨µãÐÞÊβßÂÔ£¬»ñµÃÏàÓ¦µÄÎȶ¨ÐÔÐÞÊβúÎΪÒÔºóÆäËüµ°°×ÖÊÒ©ÎïµÄ¶¨µãÐÞÊε춨»ù´¡£¬²¢¿Ë·þÏÖÓеÄPEGÐÞÊη½·¨ÖдæÔڵĿɿØÐԲÐÞÊβúÎï²»¾ùÒ»µÄȱµã¡£ |
» ²ÂÄãϲ»¶
294Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
322Çóµ÷¼Á£ºÒ»Ö¾Ô¸ºþÄÏ´óѧ ²ÄÁÏÓ뻯¹¤£¨085600£©£¬ÒѹýÁù¼¶¡£
ÒѾÓÐ14È˻ظ´
282Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
µ÷¼Á
ÒѾÓÐ9È˻ظ´
315Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ8È˻ظ´
070300»¯Ñ§Ñ§Ë¶311·ÖÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸211£¬»¯Ñ§Ñ§Ë¶£¬310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
onlliu
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2530.9
- Ìû×Ó: 379
- ÔÚÏß: 116Сʱ
- ³æºÅ: 551250
- ×¢²á: 2008-04-26
- ÐÔ±ð: GG
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
zhoudanlei(½ð±Ò+20,VIP+0): 11-16 12:21
zhoudanlei(½ð±Ò+20,VIP+0): 11-16 12:21
|
רҵ´Ê»ã×Ô¼ºÐ£Ò»Ï°É! In order to implement PEG fixed-point modification of target protein and achieve stable product of modification, as well as to lay the foundation for the future fixed-point modifications of other protein medicines, the introduction of free hydrosulfide group into protein C-terminal using approach of genetic engineering, and the introduction of imino group into protein C-terminal using modification of small molecular specificity are studied. The significance of this project is to explore the approaches of PEG fixed-point modification of two kinds of pharmaceutical protein C-terminals, to achieve resulting stable products of modification, to lay the foundation for the future fixed-point modifications of other protein medicines, and to overcome shortcomings existing in present approaches of PEG modification, e.g., poor controllability and uneven products of modification. |
2Â¥2009-11-13 22:54:33














»Ø¸´´ËÂ¥